KBP-056

**KBP-056** is a dual amylin calcitonin receptor agonist (DACRA) peptide therapeutic designed to simultaneously activate amylin receptors (AMYR) and calcitonin receptors (CALCR). Developed initially by Nordic Bioscience A/S through its subsidiary KeyBioscience AG, it was part of a 2017 collaboration with Eli Lilly, granting Lilly worldwide rights to DACRA molecules including KBP-056 for metabolic disorders. The mechanism promotes insulin sensitivity, suppresses food intake, reduces fat deposition, improves blood glucose control, and induces weight loss, positioning it as a potential treatment for type 2 diabetes and obesity. Its development status reflects preclinical to early clinical stages within the DACRA platform, with related analogs like KBP-042 advancing to Phase II.[1][3][5][10]